Which investors focus on women's health?

This blog post has been written by the person who has mapped the women's health investment market in a clean and beautiful presentation

Women's health investment has reached unprecedented levels, with $2.6 billion raised in 2024 alone.

The sector is attracting both specialized femtech funds and traditional VCs, creating new opportunities for entrepreneurs and investors. Understanding which investors are most active, their typical check sizes, and their focus areas is crucial for anyone entering this rapidly expanding market.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Who are the most active VC firms and angel investors backing women's health startups right now?

Twelve dedicated femtech funds are currently leading investments in women's health, with RH Capital, Amboy Street Ventures, and Avestria Ventures topping the list for portfolio depth and deal frequency.

Beyond dedicated funds, prominent angel networks like Alma Angels (€10M assets under management), Astia Angels, and Chloe Capital (45+ portfolio companies) are increasingly active. High-profile individual angels include Cyan Banister and Esther Dyson, who specifically seek out women-led health startups.

What are the typical funding amounts and valuation ranges these investors provide?

The average deal size in women's health reached $10.7 million per round in 2024, up from $10.4 million in 2023, with seed and Series A rounds comprising 70% of all transactions.

Early-stage deals typically range from $1-5 million for pre-seed rounds, while Series A investments average $8-15 million. Growth-stage rounds show more variation, with Series B deals ranging from $20-50 million for established companies with proven traction.

The most significant funding rounds in 2024 included Comanche Bio's $75 million Series B for preeclampsia treatment and Pomelo Care's $46 million Series B for virtual maternity care. However, a "growth-stage cliff" exists beyond Series B, where fewer investors participate in later rounds, creating opportunities for specialized growth funds.

Healthtech's share of women's health funding decreased from 54% in 2021 to 38% in 2024, while biopharma investments surged from 12% to 34% over the same period, indicating investor appetite for more regulated, higher-barrier solutions.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

Which technologies and treatment areas are attracting the most investor attention?

AI-driven diagnostics and digital therapeutics lead investment priorities, particularly for hormonal tracking, cardiovascular risk assessment in menopausal women, and reproductive health monitoring.

Reproductive and fertility technologies command significant investor interest, with companies like TMRW Life Sciences (IVF lab automation) and Juniper Genomics (whole-genome embryo screening) raising substantial rounds. The fertility market benefits from clear reimbursement pathways and measurable clinical outcomes.

Menopause and hormonal health represent the fastest-growing subsector, driven by demographic trends and previously underserved markets. Notable investments include Gesynta Pharma's $29 million seed round for non-hormonal endometriosis therapy and Hormona's €7.8 million for AI-based hormone testing.

Maternal and perinatal care solutions attract both impact-focused and returns-driven investors. Bloomlife's $13 million Series B for remote pregnancy monitoring and Comanche Bio's $75 million Series B for preeclampsia treatment demonstrate the sector's growth potential.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

Which geographic markets are seeing the highest investment volumes?

North America dominates women's health investment, accounting for approximately 60% of both deal count and total funding value, with Silicon Valley, Boston, and New York leading individual markets.

Europe shows the strongest growth trajectory, with 1.5x year-over-year increases in digital health venture capital, led by the United Kingdom, Sweden, and Israel. The European market benefits from supportive regulatory frameworks and government-backed research initiatives like the EU's €2 billion Horizon Europe women's health projects since 2020.

Asia-Pacific represents an emerging opportunity, with Australia launching government incubators backed by a AU$573 million package specifically for women's health innovation. India and Southeast Asia show selective activity through regional femtech accelerators, though total funding volumes remain modest compared to Western markets.

Latin America and the Middle East show nascent but growing investment activity, with dedicated programs like Flat6Labs Women's Health Accelerator in the MENA region focusing on family planning and fertility solutions.

How does 2024 funding compare to 2025 trends so far?

Total venture capital investment in women's health reached $2.6 billion in 2024, representing a 55% increase from 2023's $1.7 billion, while H1 2025 has already generated approximately $998 million across 18 months.

The first half of 2025 shows women's health capturing 38% of total digital health funding, indicating continued investor confidence despite broader market headwinds. The current pace suggests 2025 could match or exceed 2024's record-breaking totals if momentum sustains through the second half.

Biopharma deals are driving much of the growth, with investors increasingly comfortable with longer development timelines in exchange for stronger intellectual property protection and clearer regulatory pathways. Digital health funding has moderated from 2021-2022 peaks but remains robust for companies with proven clinical outcomes and reimbursement strategies.

Early-stage activity remains particularly strong, with seed and Series A rounds maintaining consistent deal flow throughout both years, while growth-stage funding shows more volatility based on macroeconomic conditions.

What are the largest deals and most notable transactions in recent months?

CentralReach's $1.7 billion acquisition represents the largest women's health-adjacent transaction, though the company serves broader therapy management rather than exclusively women's health.

These transactions demonstrate investor appetite for both technology-enabled services and pharmaceutical innovation, with valuations reflecting the sector's growth potential and addressable market size.

If you want to build or invest on this market, you can download our latest market pitch deck here

Which major corporations are making strategic investments in women's health?

Organon leads corporate strategic activity, co-sponsoring both Nordics and META femtech accelerators while forming partnerships with emerging startups across reproductive health and menopause care.

Private equity involvement has increased significantly, with M42 (backed by Mubadala) launching the Laha Wellness Hub focused specifically on menopause and fertility services in the Middle East market. This represents a geographic expansion of corporate interest beyond traditional US and European hubs.

Major pharmaceutical companies are expanding their women's health portfolios through both internal R&D and strategic acquisitions. PhRMA members are particularly active in developing women-specific indications for cardiovascular and autoimmune treatments, recognizing the differentiated market opportunity.

Technology giants remain less active in direct women's health investments compared to other healthcare verticals, though cloud infrastructure and AI platform partnerships are increasingly common.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

Are there funds or programs dedicated exclusively to women's health?

Twelve specialist venture capital funds focus exclusively on femtech and women's health, representing approximately $500 million in dedicated capital compared to broader healthcare funds that allocate portions of their portfolios to the sector.

Government-backed initiatives provide significant non-dilutive funding, including the US White House Initiative on Women's Health Research with $110 million in ARPA-H grants and the EU's Horizon Europe program contributing €2 billion since 2020 specifically for women's health research projects.

Corporate philanthropy plays an important role, with programs like The Case for Her in Sweden and the Better for Women Fund in the UK providing both funding and strategic guidance to early-stage companies. These programs often focus on social impact alongside financial returns.

Specialized accelerators are proliferating globally, with notable programs including 51 Labs (MATTER) in Chicago focusing on maternal mortality prevention, Flat6Labs Women's Health Accelerator in MENA, and Springboard Women's Health Accelerator providing growth funding and mentor networks in the US.

What metrics and milestones do investors prioritize before committing funding?

Clinical validation through pilot studies demonstrating safety and efficacy tops investor requirements, particularly for therapeutic and medical device companies where regulatory approval determines market access.

Clear regulatory pathways matter significantly, with investors favoring companies that understand FDA or EMA frameworks and have developed appropriate clinical trial strategies. Companies with breakthrough device designations or fast-track status receive premium valuations.

Reimbursement potential drives investment decisions, especially for digital therapeutics where payer coverage strategies determine scalability. Successful companies demonstrate early payer partnerships or clear health economic benefits that support coverage decisions.

Total addressable market analysis for specific life-stage segments proves crucial, with investors seeking companies that can quantify their opportunity within menopause, fertility, pregnancy, or other defined populations. Market sizing must account for both clinical need and willingness to pay.

Founding team expertise in clinical domains and commercialization experience significantly influences investment decisions. Investors prefer teams combining medical credentials with business execution capabilities, particularly in heavily regulated therapeutic areas.

If you need to-the-point data on this market, you can download our latest market pitch deck here

Which accelerators and incubators specifically target women's health startups?

Specialized accelerators provide crucial early-stage support, with five leading programs demonstrating strong track records for graduate success and follow-on funding rates.

These programs typically provide 3-6 month intensive support including funding ($50K-$250K), mentorship from industry experts, and connections to follow-on investors. Graduation rates and subsequent funding success vary significantly, with MATTER's 51 Labs and Springboard showing the strongest track records for Series A advancement.

What are industry forecasts predicting for women's health investment in 2026?

Industry analysts project 10-15% compound annual growth rate through 2026, driven by continued diversification into biopharma and specialty therapeutics beyond the digital health focus of previous years.

AI-powered diagnostic platforms are expected to attract significant investment, particularly for applications in early disease detection and personalized treatment selection. The convergence of artificial intelligence with women's health represents a multi-billion dollar opportunity according to leading venture firms.

Corporate strategic partnerships will likely accelerate, as pharmaceutical and healthcare companies seek to access innovation without building internal capabilities. This trend should support higher average deal sizes and more structured exit opportunities for portfolio companies.

However, macroeconomic headwinds including persistent inflation and capital market constraints may moderate late-stage funding rounds, potentially extending the growth-stage cliff that currently affects Series B+ companies. Successful companies will need stronger fundamentals and clearer paths to profitability to attract growth capital.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

Which women's health companies have successfully exited recently and who were their early backers?

Recent successful exits demonstrate the maturation of women's health as an investment category, with both IPO and acquisition activity accelerating in 2025.

Hinge Health completed a $437 million IPO in May 2025, though the company serves broader musculoskeletal health rather than women-specific conditions. Early investors included Bessemer Venture Partners and General Catalyst, who backed the company through multiple funding rounds before its public offering.

Omada Health achieved a $150 million IPO in June 2025, focusing on chronic disease management with significant women's health applications. The company's early backers included Andreessen Horowitz and GV (Google Ventures), demonstrating mainstream VC confidence in digital health platforms.

CentralReach's $1.7 billion acquisition represents the largest women's health-adjacent transaction, with therapy management applications serving autism and behavioral health providers. The company's strategic value attracted private equity buyers seeking exposure to growing healthcare technology markets.

23andMe's $305 million acquisition highlights the ongoing consolidation in personalized health and genetic testing, sectors with significant women's health applications particularly in reproductive genetics and disease risk assessment.

Not sure where the investment opportunities are? See what's emerging and where the smart money is going.

Conclusion

Sources

1. Women of Wearables - VC Funds in Women's Health
2. World Health Expo - Investment Opportunities
3. Nasdaq - Women's Health VC Investment Report
4. Papermark - Femtech Investors
5. Forbes - Women's Health Standout Year
6. Silicon Valley Bank - Women's Health Report
7. BioPharma Dive - Women's Health Funding
8. Galen Growth - Digital Health Pulse Check
9. Femtech Insider - Femtech Investors
10. World Economic Forum - Trillion Dollar Opportunity
11. Halletecco - Growth Stage Cliff
12. Flat6Labs - Women's Health Accelerator